CELLDEX THERAPEUTICS, INC.
Ownership & governance
Executives 5Directors 9Avg age 68Avg tenure 9.3y
AM
Anthony Marucci
Chief Executive Officer
Age 64Since 2008-08-31Profile →
+13
Executives5
TK
Tibor Keler→
Chief Tech/Sci/R&D Officer
Age 67Since 2014-07-29
AM
Anthony Marucci→
Chief Executive Officer
Age 64Since 2008-08-31
SM
Sam Martin→
Director of Finance/CFO
Age 55Since 2009-03-31
DY
Diane Young→
Chief Tech/Sci/R&D Officer
Age 70Since 2019-07-07
SC
Sarah Cavanaugh→
Chief Administrative Officer
Age 51Since 2017-06-14
Board of directors9
AM
Anthony Marucci→
Director/Board Member
Age 64Since 2008-11-30
HP
Harry Penner→
Chairman
Age 80Since 2025-06-04
HC
Herbert Conrad→
Director/Board Member
Age 93Since 2008-02-29
JM
James Marino→
Director/Board Member
Age 76Since 2017-03-07
KB
Keith Brownlie→
Director/Board Member
Age 73Since 2017-06-14
CC
Cheryl Cohen→
Director/Board Member
Age 60Since 2022-06-15
GN
Garry Neil→
Director/Board Member
Age 72Since 2022-06-15
RJ
Rita Jain→
Director/Board Member
Age 64Since 2023-02-15
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| Wellington Trust Co., NA | 10.91 % | 8,560,476 |
| Kynam Capital Management LP | 7.441 % | 5,840,567 |
| BlackRock Advisors LLC | 6.347 % | 4,981,577 |
| Fidelity Management & Research Co. LLC | 4.776 % | 3,749,048 |
| Point72 Asset Management LP | 4.115 % | 3,229,939 |
Catalog · 2026-07-09
Registry officers14
| Name | Role | Since | Shares |
|---|---|---|---|
| Anthony Marucci | Chief Executive Officer | 2008-08-31 | - |
| Diane Young | Chief Tech/Sci/R&D Officer | 2019-07-07 | - |
| Harry Penner | Chairman | 2025-06-04 | - |
| Sam Martin | Director of Finance/CFO | 2009-03-31 | - |
| Sarah Cavanaugh | Chief Administrative Officer | 2017-06-14 | - |
| Tibor Keler | Chief Tech/Sci/R&D Officer | 2014-07-29 | - |
| Anthony Marucci | Director/Board Member | 2008-11-30 | - |
| Cheryl Cohen | Director/Board Member | 2022-06-15 | - |
Registry · as of 2026-07-09
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus strong buyMean target 63.07Range 28–100Analysts 14
28Mean 63.07100
- Strong buy 2
- Buy 12
- Hold 1
Broker actions40 of 121
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Reiterated | Buy | 64 | 2026-10-02 |
| Leerink Partners | Maintained | Outperform | 88 | 2026-09-23 |
| Morgan Stanley | Maintained | Overweight | 57 | 2026-09-23 |
| HC Wainwright & Co. | Maintained | Buy | 64 | 2026-09-22 |
| Cantor Fitzgerald | Maintained | Overweight | 72 | 2026-09-22 |
| Morgan Stanley | Maintained | Overweight | 50 | 2026-09-10 |
| Morgan Stanley | Maintained | Overweight | 46 | 2026-08-07 |
| Barclays | Maintained | Overweight | 53 | 2026-08-07 |
| Wells Fargo | Maintained | Overweight | 72 | 2026-07-29 |
| Wells Fargo | Maintained | Overweight | 48 | 2026-07-22 |
| Morgan Stanley | Maintained | Overweight | 40 | 2026-07-22 |
| Cantor Fitzgerald | Maintained | Overweight | 61 | 2026-07-22 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.